INOVIO Provides Update on COVID-19 Heterologous Booster Vaccine Candidate, INO-4800
Excerpt from the Press Release:
PLYMOUTH MEETING, Pa., Oct. 27, 2022 /PRNewswire/ — INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and prevent infectious diseases, cancer, and diseases associated with HPV, today announced that it has discontinued its internally funded efforts to develop INO-4800 as a COVID-19 heterologous booster vaccine. The decision follows INOVIO’s comprehensive review of its portfolio, market conditions, and global demand for COVID-19 vaccines.
Dr. Jacqueline Shea, INOVIO’s CEO and President, stated: “We continue to believe that our DNA medicine technology has attributes that could be beneficial to a heterologous COVID-19 booster vaccine. However, our assessment of the current global demand for COVID-19 vaccines, changes in regulatory timelines and requirements, diminishing government financial support, and the overall growing uncertainty related to opportunities for heterologous booster vaccines have resulted in our decision to discontinue internal funding efforts to develop INO-4800 as a heterologous booster vaccine. As we work to bring DNA medicines to the marketplace, we will reallocate resources and focus our efforts on other product candidates in our pipeline, such as INO-3107 and INO-5401, both of which recently reported positive Phase 1/2 data for their respective targeted indications in recurrent respiratory papillomatosis and glioblastoma. We continue to expect to be able to report updates in the coming months from our other ongoing trials targeting Cervical High-Grade Squamous Intraepithelial Lesions (REVEAL 2), Ebola, Lassa fever and MERS.”
About INO-4800 and Ongoing COVID-19 Studies
INO-4800 is a DNA medicine product candidate that has been studied as a vaccine candidate for COVID-19. It continues to be one of the vaccines being investigated by the World Health Organization as part of their Solidarity Trial Vaccines, which is an international, multi-center, multi-vaccine, adaptive, shared placebo, event-driven, individually randomized controlled clinical trial that aims to evaluate the efficacy and safety of promising new COVID-19 vaccines.
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?